TOUR DE FORCE PRESENTATION!! - UK Special Approva
Post# of 148183
(Total Views: 618)
Posted On: 04/17/2020 4:25:38 PM
TOUR DE FORCE PRESENTATION!!
- UK Special Approval possibility. Data being sent this weekend. Meeting with CMO of U.K. sometime next week after data is reviewed!!
- Samsung will produce 1.2 million vials of Leronlimab and can increase production to 1, 2 or even 3 million vials per month if needed!!
- COVAD-19 starts as a viral infection, generally with mild symptoms, but then it MAY evolve into a immunologic disease. This is why it is so dangerous, hard to treat and potentially lethal. If we can treat this safely, could be the “key piece to societies opening up around the world.”
- Antiviral drugs NOT ENOUGH!! Most current drugs address one of the multiple facets causing this deadly disease. Leronlimab is the only medication that addresses all of these facet. Scientific proof to be published in (hopefully) 6 weeks. WORLD WILL UNDERSTAND WHY LERONLIMAB IS UNIQUE!!
- BLA info has been received, all of it. Should be able to complete the filing by end of next week!!
- Total addressable market is much larger than COVID-19 market. Should be useful to combat severe influenza as well. Possibly in conjunction with existing effective anti virals designed for influenza.
- Could be useful for many other auto-immune indications. Exciting future without even adding HIV and cancer treatment potential!!!!!!
- UK Special Approval possibility. Data being sent this weekend. Meeting with CMO of U.K. sometime next week after data is reviewed!!
- Samsung will produce 1.2 million vials of Leronlimab and can increase production to 1, 2 or even 3 million vials per month if needed!!
- COVAD-19 starts as a viral infection, generally with mild symptoms, but then it MAY evolve into a immunologic disease. This is why it is so dangerous, hard to treat and potentially lethal. If we can treat this safely, could be the “key piece to societies opening up around the world.”
- Antiviral drugs NOT ENOUGH!! Most current drugs address one of the multiple facets causing this deadly disease. Leronlimab is the only medication that addresses all of these facet. Scientific proof to be published in (hopefully) 6 weeks. WORLD WILL UNDERSTAND WHY LERONLIMAB IS UNIQUE!!
- BLA info has been received, all of it. Should be able to complete the filing by end of next week!!
- Total addressable market is much larger than COVID-19 market. Should be useful to combat severe influenza as well. Possibly in conjunction with existing effective anti virals designed for influenza.
- Could be useful for many other auto-immune indications. Exciting future without even adding HIV and cancer treatment potential!!!!!!
(7)
(0)CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼